One Ascent Financial Services LLC Argenx Se Transaction History

One Ascent Financial Services LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 13, 2023	BUY	$369.35 - $548.43 $165,838 - $246,245	449 New	449 $221,000
Q2 2022 Aug 08, 2022	SELL	$269.58 - $378.88 $34,506 - $48,496	-128 Reduced 16.71%	638 $242,000
Q1 2022 May 12, 2022	BUY	$254.45 - $351.06 $194,908 - $268,911	766 New	766 $242,000
Q3 2020 Nov 02, 2020	SELL	$215.51 - $272.51 $302,791 - $382,876	-1,405 Closed	0 $0
Q2 2020 Jul 21, 2020	BUY	$127.44 - $232.72 $179,053 - $326,971	1,405 New	1,405 $316,000
Q1 2020 Apr 14, 2020	SELL	$108.83 - $165.23 $245,955 - $373,419	-2,260 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$106.59 - $164.21 $240,893 - $371,114	2,260 New	2,260 $363,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of One Ascent Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on One Ascent Financial Services LLC with notifications on news.